Board Meeting-Appointment of Director
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the Company, at its meeting held on Tuesday, March 27, 2018, has appointed Mr. Saurin J. Parikh as an Additional Director (categorised as an Independent Director) on the Board of the Company. Financial Results For Quarter And Nine-Months Ended On December 31, 2017
we would like to inform that the Board of Directors of the Company at their meeting held today, i.e. on Wednesday, January 31, 2018 have considered and approved the Standalone and Consolidated Un-Audited Financial Results of the Company for the Quarter and Nine-Months Ended on December 31, 2017. Outcome of Board Meeting
we would like to inform that the Board of Directors of the Company at their meeting held today, i.e. on Wednesday, January 31, 2018 have considered and approved the Standalone and Consolidated Un-Audited Financial Results of the Company for the Quarter and Nine-Months Ended on December 31, 2017. Closure of Trading Window
The Meeting of the Board of Directors of the Company will be held on Wednesday, January 31, 2018 to consider and approve the Un-Audited Standalone and Consolidated Financial Results of the Company for the Quarter and Nine-Months Ended on December 31, 2017. Pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 and in accordance with the Code of Conduct to Regulate, Monitor and Report Trading by Insiders for trading in listed... Board Meeting On January 31, 2018
Meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, January 31, 2018 at the Registered Office of the Company inter-alia to consider and approve the Un-Audited Standalone and Consolidated Financial Results of the Company for the Quarter and Nine-Months Ended on December 31, 2017. Shareholding for the Period Ended December 31, 2017
Lincoln Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2017. For more details, kindly Click here Statement Of Investor Complaints For The Quarter Ended December 31, 2017
Enclosed the Copy of Investors Complaint for the Quarter Ended on December 31, 2017. Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mahendrabhai Gulabdas Patel Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Munjal Mahendrabhai Patel Lincoln Pharma gets patent for anti-malarial drug
The drug is painless and gives faster relief to the patients, Lincoln Pharma said